SLC5A2 and type 2 diabetes mellitus: The decrease in serum urate levels with the use of SGLT2 inhibitors has alsobeen demonstrated in patients without T2DM compared to placebo as a recentmeta-analysis showed (–91.38 μmol/L; 95% CI: –126.53 to –56.24),although further randomized controlled trials are now recommended to confirmthese data [59].